東寶生物(300239.SZ):國恩股份成為公司控股股東、
格隆匯8月6日丨東寶生物(300239.SZ)公佈,公司於2021年8月6日收到東寶實業通知,協議轉讓股份的過户登記手續已辦理完畢,並取得中國證券登記結算有限責任公司於2021年8月6日出具的《證券過户登記確認書》。東寶實業已將其持有的公司6000萬股股票過户登記至國恩股份。 此次協議轉讓過户登記完成前後權益變動情況如下:

此次協議轉讓過户登記完成後,國恩股份持有公司125,711,022 股股票,佔公司總股本的21.14%,為公司的控股股東。王愛國、徐波為公司實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.